Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.
COVID-19
acute respiratory distress syndrome
anakinra
intensive care unit
mechanical ventilation
tocilizumab
Journal
Multidisciplinary respiratory medicine
ISSN: 1828-695X
Titre abrégé: Multidiscip Respir Med
Pays: Italy
ID NLM: 101477642
Informations de publication
Date de publication:
15 Jan 2021
15 Jan 2021
Historique:
received:
22
11
2020
accepted:
19
02
2021
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit. The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching. Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission. Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation.
Sections du résumé
BACKGROUND
BACKGROUND
The use of cytokine-blocking agents has been proposed to modulate the inflammatory response in patients with COVID-19. Tocilizumab and anakinra were included in the local protocol as an optional treatment in critically ill patients with acute respiratory distress syndrome (ARDS) by SARS-CoV-2 infection. This cohort study evaluated the effects of therapy with cytokine blocking agents on in-hospital mortality in COVID-19 patients requiring mechanical ventilation and admitted to intensive care unit.
METHODS
METHODS
The association between therapy with tocilizumab or anakinra and in-hospital mortality was assessed in consecutive adult COVID-19 patients admitted to our ICU with moderate to severe ARDS. The association was evaluated by comparing patients who received to those who did not receive tocilizumab or anakinra and by using different multivariable Cox models adjusted for variables related to poor outcome, for the propensity to be treated with tocilizumab or anakinra and after patient matching.
RESULTS
RESULTS
Sixty-six patients who received immunotherapy (49 tocilizumab, 17 anakinra) and 28 patients who did not receive immunotherapy were included. The in-hospital crude mortality was 30,3% in treated patients and 50% in nontreated (OR 0.77, 95% CI 0.56-1.05, p=0.069). The adjusted Cox model showed an association between therapy with immunotherapy and in-hospital mortality (HR 0.40, 95% CI 0.19-0.83, p=0.015). This protective effect was further confirmed in the analysis adjusted for propensity score, in the propensity-matched cohort and in the cohort of patients with invasive mechanical ventilation within 2 hours after ICU admission.
CONCLUSIONS
CONCLUSIONS
Although important limitations, our study showed that cytokine-blocking agents seem to be safe and to improve survival in COVID-19 patients admitted to ICU with ARDS and the need for mechanical ventilation.
Identifiants
pubmed: 34040779
doi: 10.4081/mrm.2021.737
pmc: PMC8139121
doi:
Types de publication
Journal Article
Langues
eng
Pagination
737Informations de copyright
Copyright: the Author(s).
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Med Virol. 2020 Oct;92(10):2042-2049
pubmed: 32369191
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
J Med Virol. 2020 Nov;92(11):2813-2820
pubmed: 32628003
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Lancet Respir Med. 2020 Jun;8(6):e46-e47
pubmed: 32353251
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
PLoS One. 2020 Apr 22;15(4):e0231896
pubmed: 32320454
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Lancet Rheumatol. 2020 Oct;2(10):e603-e612
pubmed: 32838323
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532
pubmed: 32359035
Rheumatol Ther. 2018 Jun;5(1):21-42
pubmed: 29502236
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet Rheumatol. 2020 Jun;2(6):e358-e367
pubmed: 32373790
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
J Intern Med. 2021 Mar;289(3):434-436
pubmed: 32744399
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Semin Immunol. 2013 Dec 15;25(6):469-84
pubmed: 24275598
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758